Pilotto, Andrea http://orcid.org/0000-0003-2029-6606
Ashton, Nicholas J.
Lupini, Alessandro
Battaglio, Beatrice
Zatti, Cinzia
Trasciatti, Chiara
Gipponi, Stefano
Cottini, Elisabetta
Grossi, Ilaria
Salvi, Alessandro
de Petro, Giuseppina
Pizzi, Marina
Canale, Antonio
Blennow, Kaj
Zetterberg, Henrik
Padovani, Alessandro
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (2017MYJ5TH)
RePlast (PRIN 2021)
Airalzh Foundation (AGYR2021)
Health and Wealth research grants 2016 of the University of Brescia (number NP 1471, DMA)
H2020 European Research Council (ID853981)
Ministero della Salute (RF-2018-12366209)
PNRR-Health (PNRR-MAD-2022-12376110)
Swedish Research Council (2017-00915)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Office of Dietary Supplements (1R01AG068398-01)
Swedish Research Council (2022-01018, 2019-02397)
HORIZON EUROPE Reforming and enhancing the European Research and Innovation system (101053962)
Swedish State Support for Clinical Research (ALFGBG-71320)
Alzheimer Drug Discovery Foundation (ADDF)
AD Strategic Fund and the Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C)
Bluefield Project
Familjen Erling-Perssons Stiftelse
Stiftelsen för Gamla Tjänarinnor (FO2022-0270)
H2020 Marie Skłodowska-Curie Actions (860197 (MIRIADE))
EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UCLH Biomedical Research Centre (UKDRI-1003)
Università degli Studi di Brescia
Article History
Received: 17 May 2024
Revised: 26 August 2024
Accepted: 27 August 2024
First Online: 9 September 2024
Declarations
:
: All the authors report no disclosures related to this manuscript. Andrea Pilotto served in the advisory board of Z-cube (technology division of Zambon pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Nutricia and Chiesi Pharmaceuticals. He received research support from Vitaflo Germany and Zambon Italy. Nicholas Ashton has no financial conflicts to disclose. Alessandro Lupini has no financial conflicts to disclose. Beatrice Battaglio has no financial conflicts to disclose. Cinzia Zatti has no financial conflicts to disclose. Chiara Trasciatti has no financial conflicts to disclose. Stefano Gipponi has no financial conflicts to disclose. Elisabetta Cottini has no financial conflicts to disclose. Ilaria Grossi has no financial conflicts to disclose. Alessandro Salvi has no financial conflicts to disclose. Giuseppina De Petro has no financial conflicts to disclose. Marina Pizzi has no financial conflicts to disclose. Antonio Canale has no financial conflicts to disclose. Kaj Blennow has no financial conflicts to disclose. Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma, and Chiesi Pharmaceuticals. He is founded by Grant of M1.